153 related articles for article (PubMed ID: 19808977)
1. In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.
Zheng B; Fuji RN; Elkins K; Yu SF; Fuh FK; Chuh J; Tan C; Hongo JA; Raab H; Kozak KR; Williams M; McDorman E; Eaton D; Ebens A; Polson AG
Mol Cancer Ther; 2009 Oct; 8(10):2937-46. PubMed ID: 19808977
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.
Fuh FK; Looney C; Li D; Poon KA; Dere RC; Danilenko DM; McBride J; Reed C; Chung S; Zheng B; Mathews WR; Polson A; Prabhu S; Williams M
Br J Pharmacol; 2017 Apr; 174(8):628-640. PubMed ID: 28009435
[TBL] [Abstract][Full Text] [Related]
3. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.
Li D; Lee D; Dere RC; Zheng B; Yu SF; Fuh FK; Kozak KR; Chung S; Bumbaca Yadav D; Nazzal D; Danilenko D; Go MAT; Williams M; Polson AG; Poon KA; Prabhu S
Br J Pharmacol; 2019 Oct; 176(19):3805-3818. PubMed ID: 31270798
[TBL] [Abstract][Full Text] [Related]
4. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.
Polson AG; Yu SF; Elkins K; Zheng B; Clark S; Ingle GS; Slaga DS; Giere L; Du C; Tan C; Hongo JA; Gogineni A; Cole MJ; Vandlen R; Stephan JP; Young J; Chang W; Scales SJ; Ross S; Eaton D; Ebens A
Blood; 2007 Jul; 110(2):616-23. PubMed ID: 17374736
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.
Polson AG; Williams M; Gray AM; Fuji RN; Poon KA; McBride J; Raab H; Januario T; Go M; Lau J; Yu SF; Du C; Fuh F; Tan C; Wu Y; Liang WC; Prabhu S; Stephan JP; Hongo JA; Dere RC; Deng R; Cullen M; de Tute R; Bennett F; Rawstron A; Jack A; Ebens A
Leukemia; 2010 Sep; 24(9):1566-73. PubMed ID: 20596033
[TBL] [Abstract][Full Text] [Related]
6. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.
Polson AG; Calemine-Fenaux J; Chan P; Chang W; Christensen E; Clark S; de Sauvage FJ; Eaton D; Elkins K; Elliott JM; Frantz G; Fuji RN; Gray A; Harden K; Ingle GS; Kljavin NM; Koeppen H; Nelson C; Prabhu S; Raab H; Ross S; Slaga DS; Stephan JP; Scales SJ; Spencer SD; Vandlen R; Wranik B; Yu SF; Zheng B; Ebens A
Cancer Res; 2009 Mar; 69(6):2358-64. PubMed ID: 19258515
[TBL] [Abstract][Full Text] [Related]
8. Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity.
Shen Y; Yang T; Cao X; Zhang Y; Zhao L; Li H; Zhao T; Xu J; Zhang H; Guo Q; Cai J; Gao B; Yu H; Yin S; Song R; Wu J; Guan L; Wu G; Jin L; Su Y; Liu Y
MAbs; 2019; 11(6):1149-1161. PubMed ID: 31161871
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.
Dornan D; Bennett F; Chen Y; Dennis M; Eaton D; Elkins K; French D; Go MA; Jack A; Junutula JR; Koeppen H; Lau J; McBride J; Rawstron A; Shi X; Yu N; Yu SF; Yue P; Zheng B; Ebens A; Polson AG
Blood; 2009 Sep; 114(13):2721-9. PubMed ID: 19633198
[TBL] [Abstract][Full Text] [Related]
10. Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies.
Yadav R; Sukumaran S; Zabka TS; Li J; Oldendorp A; Morrow G; Reyes A; Cheu M; Li J; Wallin JJ; Tsai S; Sun L; Wang P; Ellerman D; Spiess C; Polson A; Stefanich EG; Kamath AV; Ovacik MA
Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631556
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b.
Jahn L; Hombrink P; Hassan C; Kester MG; van der Steen DM; Hagedoorn RS; Falkenburg JH; van Veelen PA; Heemskerk MH
Blood; 2015 Feb; 125(6):949-58. PubMed ID: 25414443
[TBL] [Abstract][Full Text] [Related]
12. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
13. B-cell inhibition by cross-linking CD79b is superior to B-cell depletion with anti-CD20 antibodies in treating murine collagen-induced arthritis.
Brühl H; Cihak J; Talke Y; Rodriguez Gomez M; Hermann F; Goebel N; Renner K; Plachý J; Stangassinger M; Aschermann S; Nimmerjahn F; Mack M
Eur J Immunol; 2015 Mar; 45(3):705-15. PubMed ID: 25471597
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation of
Hartimath SV; Alizadeh E; Solomon VR; Chekol R; Bernhard W; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
J Nucl Med; 2019 Aug; 60(8):1103-1110. PubMed ID: 30655327
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.
Pfeifer M; Zheng B; Erdmann T; Koeppen H; McCord R; Grau M; Staiger A; Chai A; Sandmann T; Madle H; Dörken B; Chu YW; Chen AI; Lebovic D; Salles GA; Czuczman MS; Palanca-Wessels MC; Press OW; Advani R; Morschhauser F; Cheson BD; Lenz P; Ott G; Polson AG; Mundt KE; Lenz G
Leukemia; 2015 Jul; 29(7):1578-86. PubMed ID: 25708834
[TBL] [Abstract][Full Text] [Related]
16. Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies.
Wang J; Li C; He K; Kuang Z; Lu J; Yao Y; He F; Li N; Li L; Fu F; Wu Z; Zhou S; Kang D; Qiu X; Wu M; Liu Y; Cao X; Xu M; Chen B; Wu W; Guo F
Cancer Immunol Immunother; 2023 Feb; 72(2):493-507. PubMed ID: 35963895
[TBL] [Abstract][Full Text] [Related]
17. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T
Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201
[TBL] [Abstract][Full Text] [Related]
18. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.
Erickson HK; Lewis Phillips GD; Leipold DD; Provenzano CA; Mai E; Johnson HA; Gunter B; Audette CA; Gupta M; Pinkas J; Tibbitts J
Mol Cancer Ther; 2012 May; 11(5):1133-42. PubMed ID: 22408268
[TBL] [Abstract][Full Text] [Related]
19. Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.
Perrino E; Steiner M; Krall N; Bernardes GJ; Pretto F; Casi G; Neri D
Cancer Res; 2014 May; 74(9):2569-78. PubMed ID: 24520075
[TBL] [Abstract][Full Text] [Related]
20. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
